Mapping the knowledge landscape of Pseudomonas aeruginosa biofilm-mediated drug resistance: a bibliometric analysis and clinical trial landscape overview
Abstract
Background: Pseudomonas aeruginosa is a major opportunistic pathogen whose ability to form biofilms greatly enhances antimicrobial tolerance and contributes to persistent infection. Although increasing attention has been paid to biofilm-mediated drug resistance, the overall knowledge structure and translational development of this field remain unclear.
Methods: A bibliometric analysis was performed using publications retrieved from the Web of Science Core Collection and Scopus on December 20, 2025. The search covered the period 2014-2025 and focused on P. aeruginosa, antimicrobial resistance, and biofilms, resulting in 6,537 publications for bibliometric analysis. To complement the bibliometric findings, a supplementary narrative review of published clinical studies and a separate registered trial landscape overview were conducted. After screening, 6 published clinical studies and 18 registered interventional trials were included.
Results: Global research output on P. aeruginosa biofilm-mediated resistance increased steadily from 2014 to 2025. China, the United States, and India were the most productive countries, while the United States showed the leading role in the international collaboration network. Keyword clustering and temporal analyses indicated three major research directions: multidrug resistance evolution and pathogenic synergy, novel antibacterial interventions and functional materials, and clinical translation and efficacy evaluation. The supplementary clinical…
Read the paper
Related studies
- Horizontal gene transfer in the human gastrointestinal tract: potential spread of antibiotic resistance genes
- Mutation supply and relative fitness shape the genotypes of ciprofloxacin-resistant Escherichia coli
- Genomic Survey of E. coli From the Bladders of Women With and Without Lower Urinary Tract Symptoms
- Characterization of cefotaxime-resistant urinary Escherichia coli from primary care in South-West England 2017–18
- Fitness cost constrains the spectrum of marR mutations in ciprofloxacin-resistant Escherichia coli
- Emerging evidence-based innovative approaches to control catheter-associated urinary tract infection: a review
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.